Praphan Phanuphak1, Sunee Sirivichayakul, Awachana Jiamsakul, Somnuek Sungkanuparph, Nagalingeswaran Kumarasamy, Man Po Lee, Thira Sirisanthana, Pacharee Kantipong, Christopher Lee, Adeeba Kamarulzaman, Mahiran Mustafa, Rossana Ditangco, Tuti Merati, Winai Ratanasuwan, Thida Singtoroj, Rami Kantor. 1. *HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand; †Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; ‡The Kirby Institute, Faculty of Medicine, University of New South Wales, Sydney, Australia; §Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; ‖YRG Centre for AIDS Research and Education, Chennai, India; ¶Queen Elizabeth Hospital, Hong Kong, China; #Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; **Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand; ††Hospital Sungai Buloh, Kuala Lumpur, Malaysia; ‡‡University of Malaya, Kuala Lumpur, Malaysia; §§Hospital Raja Perempuan Zainab II, Kota Bharu, Malaysia; ‖‖Research Institute for Tropical Medicine, Manila, Philippines; ¶¶Faculty of Medicine, Udayana University and Sanglah Hospital, Bali, Indonesia; ##Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; ***TREAT Asia, amfAR-The Foundation for AIDS Research, Bangkok, Thailand; and †††Brown University Alpert Medical School, Providence, RI.
Abstract
BACKGROUND: We compared treatment outcomes of transmitted drug resistance (TDR) in patients on fully or partially sensitive drug regimens. METHODS: Factors associated with survival and failure were analyzed using Cox proportional hazards and discrete time conditional logistic models. RESULTS: TDR, found in 60 (4.1%) of 1471 Asian treatment-naive patients, was one of the significant predictors of failure. Patients with TDR to >1 drug in their regimen were >3 times as likely to fail compared to no TDR. CONCLUSIONS: TDR was associated with failure in the context of non-fully sensitive regimens. Efforts are needed to incorporate resistance testing into national treatment programs.
BACKGROUND: We compared treatment outcomes of transmitted drug resistance (TDR) in patients on fully or partially sensitive drug regimens. METHODS: Factors associated with survival and failure were analyzed using Cox proportional hazards and discrete time conditional logistic models. RESULTS: TDR, found in 60 (4.1%) of 1471 Asian treatment-naive patients, was one of the significant predictors of failure. Patients with TDR to >1 drug in their regimen were >3 times as likely to fail compared to no TDR. CONCLUSIONS: TDR was associated with failure in the context of non-fully sensitive regimens. Efforts are needed to incorporate resistance testing into national treatment programs.
Authors: M C Weinstein; S J Goldie; E Losina; C J Cohen; J D Baxter; H Zhang; A D Kimmel; K A Freedberg Journal: Ann Intern Med Date: 2001-03-20 Impact factor: 25.391
Authors: Tulio de Oliveira; Koen Deforche; Sharon Cassol; Mika Salminen; Dimitris Paraskevis; Chris Seebregts; Joe Snoeck; Estrelita Janse van Rensburg; Annemarie M J Wensing; David A van de Vijver; Charles A Boucher; Ricardo Camacho; Anne-Mieke Vandamme Journal: Bioinformatics Date: 2005-08-02 Impact factor: 6.937
Authors: Paul E Sax; Runa Islam; Rochelle P Walensky; Elena Losina; Milton C Weinstein; Sue J Goldie; Sara N Sadownik; Kenneth A Freedberg Journal: Clin Infect Dis Date: 2005-09-23 Impact factor: 9.079
Authors: Susan J Little; Sarah Holte; Jean-Pierre Routy; Eric S Daar; Marty Markowitz; Ann C Collier; Richard A Koup; John W Mellors; Elizabeth Connick; Brian Conway; Michael Kilby; Lei Wang; Jeannette M Whitcomb; Nicholas S Hellmann; Douglas D Richman Journal: N Engl J Med Date: 2002-08-08 Impact factor: 91.245
Authors: Annemarie M J Wensing; David A van de Vijver; Gioacchino Angarano; Birgitta Asjö; Claudia Balotta; Enzo Boeri; Ricardo Camacho; Maire-Laure Chaix; Dominique Costagliola; Andrea De Luca; Inge Derdelinckx; Zehava Grossman; Osamah Hamouda; Angelos Hatzakis; Robert Hemmer; Andy Hoepelman; Andrzej Horban; Klaus Korn; Claudia Kücherer; Thomas Leitner; Clive Loveday; Eilidh MacRae; Irina Maljkovic; Carmen de Mendoza; Laurence Meyer; Claus Nielsen; Eline L Op de Coul; Vidar Ormaasen; Dimitris Paraskevis; Luc Perrin; Elisabeth Puchhammer-Stöckl; Lidia Ruiz; Mika Salminen; Jean-Claude Schmit; Francois Schneider; Rob Schuurman; Vincent Soriano; Grzegorz Stanczak; Maja Stanojevic; Anne-Mieke Vandamme; Kristel Van Laethem; Michela Violin; Karin Wilbe; Sabine Yerly; Maurizio Zazzi; Charles A Boucher Journal: J Infect Dis Date: 2005-08-15 Impact factor: 5.226
Authors: Martin S Hirsch; Françoise Brun-Vézinet; Bonaventura Clotet; Brian Conway; Daniel R Kuritzkes; Richard T D'Aquila; Lisa M Demeter; Scott M Hammer; Victoria A Johnson; Clive Loveday; John W Mellors; Donna M Jacobsen; Douglas D Richman Journal: Clin Infect Dis Date: 2003-06-23 Impact factor: 9.079
Authors: Mark J Giganti; Paula M Luz; Yanink Caro-Vega; Carina Cesar; Denis Padgett; Serena Koenig; Juan Echevarria; Catherine C McGowan; Bryan E Shepherd Journal: AIDS Res Hum Retroviruses Date: 2015-03-06 Impact factor: 2.205
Authors: Awachana Jiamsakul; Stephen J Kerr; Oon Tek Ng; Man Po Lee; Romanee Chaiwarith; Evy Yunihastuti; Kinh Van Nguyen; Thuy Thanh Pham; Sasisopin Kiertiburanakul; Rossana Ditangco; Vonthanak Saphonn; Benedict L H Sim; Tuti Parwati Merati; Wingwai Wong; Pacharee Kantipong; Fujie Zhang; Jun Yong Choi; Sanjay Pujari; Adeeba Kamarulzaman; Shinichi Oka; Mahiran Mustafa; Winai Ratanasuwan; Boondarika Petersen; Matthew Law; Nagalingeswaran Kumarasamy Journal: Trop Med Int Health Date: 2016-03-29 Impact factor: 2.622
Authors: Theppharit Panichsillapakit; Davey M Smith; Joel O Wertheim; Douglas D Richman; Susan J Little; Sanjay R Mehta Journal: J Acquir Immune Defic Syndr Date: 2016-02-01 Impact factor: 3.731
Authors: Silvia Bertagnolio; Rachel L Beanland; Michael R Jordan; Meg Doherty; Gottfried Hirnschall Journal: J Infect Dis Date: 2017-12-01 Impact factor: 5.226